We will provide medical applications in two fields:
Application Group A: Supporting clinical decision making
Here, we decided to focus on examples from the cancer field where the translational effect can be illustrated. We plan to expand the program in the second funding phase.
Application Group B: Novel Phenotypes (“LIFE-Atlas”)
In this group of applications we address an emerging issue in system medicine. In the field of epidemiological research dedicated to investigate the risk for civilization diseases we are presently gaining data from novel assessment technologies (e.g. 3D-body shape, MRI, optical coherence tomography, liver elastography, vessel stiffness, transcriptome, metabolome, multichannel FACS cytomics). These methods provide quantitative and qualitative traits (QTs). They need to be characterized on a population level. The next challenging task is to investigate from a systems medicine perspective which of these QTs can be combined into reliable phenotype-profiles. It would e.g. be relevant to find out which obese persons have a low risk profile for onset of diabetes, hypertension or vessel disease (low risk “healthy obese”). We will utilize the LIFE ADULT and the LIFE HEART cohorts.
In the LIFE-ADULT cohort we have 10.000 participants from the Leipzig population. The have undergone extensive assessments: e.g. 3D-body shapes (10000), OCT-retina measurements (10000), metabolic traits (10000), vessel status assessments (8000), Brain MRI-scans (3000), WBC transcriptomes, genotypes and MS-metaboloms (3500). On the HEART cohort we have phenotype status including coronarography and WBC transcriptoms / genotypes / metaboloms on 7000 patients [86, 87-95, 105].